- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

S. 832
U.S. Senate•In Senate Committee
Summary
S. 832, the EPIC Act of 2025, was introduced in the Senate on Mar 4, 2025 by Sen. Thom Tillis (R) with 7 co-sponsors. It was referred to Finance, and last saw action on Mar 4, 2025: Read twice and referred to the Committee on Finance.
Record
Text
S. 832 has 7 co-sponsors.
sb832/introduced-in-senate.txt119 S832 IS: Ensuring Pathways to Innovative Cures Act of 2025U.S. Senate2025-03-04text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.II 119th CONGRESS 1st Session S. 832 IN THE SENATE OF THE UNITED STATES March 4, 2025 Mr. Tillis (for himself, Mr. Budd , Mrs. Blackburn , Mr. Daines , and Mr. Lankford ) introduced the following bill; which was read twice and referred to the Committee on Finance A BILLTo amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.1.Short titleThis Act may be cited as the Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 .2.Equalizing the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation ProgramSection 1192(e)(1)(A)(ii) of the Social Security Act ( 42 U.S.C. 1320f–1(e)(1)(A)(ii) ) is amended—(1)by striking year, at least 7 and inserting “year—(I)for initial price applicability years 2026 and 2027, at least 7; and(2)by adding at the end the following:(II)for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and.
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2025-03-04
- Passed Senate
- Passed House
- Conference
- To President
- Became Law
CRS Summary
The summaries are the Congressional Research Service’s, one per stage. Read them in full.
Introduced in Senate Mar 4, 2025
sb832/introduced-in-senate.mdShown Here:
Introduced in Senate (03/04/2025)
Sponsors
Sen. Thom Tillis (R) sponsors S. 832, and 7 members have co-sponsored it, 4 of them from the day it was introduced.

Sen. · R–NC · Sponsor
Introduced Mar 4, 2025

Sen. · R–TN · Co-sponsor
Joined Mar 4, 2025 · Original

Sen. · R–NC · Co-sponsor
Joined Mar 4, 2025 · Original

Sen. · R–MT · Co-sponsor
Joined Mar 4, 2025 · Original

Sen. · R–OK · Co-sponsor
Joined Mar 4, 2025 · Original

Sen. · R–UT · Co-sponsor
Joined Apr 10, 2025

Sen. · R–IN · Co-sponsor
Joined Apr 29, 2025

Sen. · R–KS · Co-sponsor
Joined Apr 29, 2025
Committees
S. 832 went before 1 committee: Finance.
Actions
S. 832 has taken 2 actions since Mar 4, 2025.
| Chamber | Action | |||
|---|---|---|---|---|
Mar 4, 2025 | Senate | Read twice and referred to the Committee on Finance.Finance Committee | ||
Mar 4, 2025 | — | Introduced in Senate |
Votes
S. 832 has not gone to a roll call.
Titles
S. 832 goes by 4 titles, 2 of them short titles.
- EPIC Act of 2025 — Display Title
- EPIC Act of 2025 — Short Title(s) as Introduced
- Ensuring Pathways to Innovative Cures Act of 2025 — Short Title(s) as Introduced
- A bill to amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. — Official Title as Introduced
Lobbying
34 clients hired 40 firms and 248 registered lobbyists who named S. 832 in 196 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Health Issues, Medicare/Medicaid, Trade (domestic/foreign), Budget/Appropriations, Taxation/Internal Revenue Code, Copyright/Patent/Trademark, Pharmacy, Labor Issues/Antitrust/Workplace.
Clients
Who paid to be heard, by how many filings named the bill. The 20 that filed most often, of 34.
| Client | Business | State | Firms | Filings | Reported |
|---|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | Trade association of innovative biopharmaceutical research companies. | District of Columbia | 5 | 25 | $940K |
| NOVARTIS | Innovative medicines company. | District of Columbia | 2 | 13 | $280K |
| PHRMA | Represents country's leading pharmaceutical research and biotechnology companies | District of Columbia | 3 | 11 | $630K |
| NOVARTIS, INC. | Multinational biopharmaceutical company | District of Columbia | 2 | 9 | $500K |
| JOB CREATORS NETWORK | advocacy organization for small business | Texas | 1 | 9 | $55.5K |
| BAYER CORPORATION (CONSOLIDATED REPORT) | — | District of Columbia | 1 | 9 | — |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | trade group representing U.S. pharmaceutical research and biotechnology companies | District of Columbia | 2 | 8 | $290K |
| BOEHRINGER INGELHEIM USA CORPORATION | Lobbyists | District of Columbia | 1 | 8 | — |
| SOLENO THERAPEUTICS, INC. | Soleno is focused on development of novel therapeutics for treatment of rare diseases. | California | 2 | 7 | $170K |
| GSK (FKA GLAXOSMITHKLINE INC.) | — | District of Columbia | 1 | 7 | — |
| LUNDBECK LLC | — | District of Columbia | 1 | 7 | — |
| PUBLIC CITIZEN | — | District of Columbia | 1 | 7 | — |
| TAKEDA PHARMACEUTICALS AMERICA INC | — | District of Columbia | 1 | 7 | — |
| EMD SERONO INC | — | District of Columbia | 1 | 6 | — |
| HEALTHCARE INSTITUTE OF NEW JERSEY | — | New Jersey | 1 | 6 | — |
| JOHNSON & JOHNSON SERVICES INC | — | New Jersey | 1 | 6 | — |
| NEUROCRINE BIOSCIENCES, INC | — | California | 1 | 6 | — |
| CONSERVATIVES FOR PROPERTY RIGHTS | Coalition | South Carolina | 1 | 5 | $188K |
| BIOGEN | — | District of Columbia | 1 | 5 | — |
| PERSONALIZED MEDICINE COALITION | Health care | District of Columbia | 1 | 5 | — |
Firms
Registrants who filed on the bill, by filings.
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 248.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| KARINA LYNCH | 1 | 3 | 12 |
| MARGARET MARTIN | 1 | 3 | 12 |
| RICHARD BURR | 1 | 3 | 12 |
| VINCENT SARUBBI | 1 | 2 | 11 |
| BRIAN NAGLE | 1 | 1 | 9 |
| ERICK LUTT | 1 | 1 | 9 |
| JIM TRAVIS | 1 | 1 | 9 |
| KAREN HARNED | 1 | 1 | 9 |
| MICHAEL HOLLAND | 1 | 1 | 9 |
| MICHAEL PARRISH | 1 | 1 | 9 |
| STEPHANIE MURPHY | 1 | 1 | 9 |
| COURTNEY LEE-ASHLEY | 1 | 1 | 8 |
| COURTNEY PIRON | 1 | 1 | 8 |
| JOSEPH MCGOWAN | 1 | 1 | 8 |
| KATHARINE BOND | 1 | 1 | 8 |
| SARAH DURR | 1 | 1 | 8 |
| SARAH NORDSTROM | 1 | 1 | 8 |
| TAYLOR BOOTH | 1 | 1 | 8 |
| THOMAS SUTER | 1 | 1 | 8 |
| ANDREW KAPLAN | 1 | 1 | 7 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 first_quarter | $12.9M | 1st Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2026 first_quarter | $12.2M | 1st Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 third_quarter | $9M | 3rd Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 fourth_quarter | $8.4M | 4th Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 second_quarter | $7.6M | 2nd Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2026 second_quarter | $7.4M | 2nd Quarter - Report |
| AARP | AARP | 2025 fourth_quarter | $5.3M | 4th Quarter - Report |
| AARP | AARP | 2025 second_quarter | $5.1M | 2nd Quarter - Report |
| NOVARTIS | NOVARTIS | 2025 first_quarter | $4.2M | 1st Quarter - Report |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2025 first_quarter | $4.1M | 1st Quarter - Report |
| NOVARTIS | NOVARTIS | 2026 first_quarter | $3.9M | 1st Quarter - Report |
| AARP | AARP | 2025 third_quarter | $3.8M | 3rd Quarter - Report |
| JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | 2026 first_quarter | $3.5M | 1st Quarter - Report |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2025 second_quarter | $3.4M | 2nd Quarter - Report |
| JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | 2025 first_quarter | $3.3M | 1st Quarter - Report |
| BAYER CORPORATION (CONSOLIDATED REPORT) | BAYER CORPORATION (CONSOLIDATED REPORT) | 2025 first_quarter | $3M | 1st Quarter - Report |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2025 third_quarter | $2.9M | 3rd Quarter - Report |
| SANOFI US SERVICES INC | SANOFI US SERVICES INC. | 2026 first_quarter | $2.6M | 1st Quarter - Report |
| SANOFI US SERVICES INC | SANOFI US SERVICES INC. | 2025 first_quarter | $2.5M | 1st Quarter - Report |
| BAYER CORPORATION (CONSOLIDATED REPORT) | BAYER CORPORATION (CONSOLIDATED REPORT) | 2025 second_quarter | $2.5M | 2nd Quarter - Report |
Classification
The Congressional Research Service files S. 832 under Health, one of its 31 policy areas.
CRS Subjects
CRS assigns every bill one policy area from its 31; S. 832’s is Health.
s832/policy-areas.txtSource: congress.gov · legiscan.com